Legorreta Pablo G.
SEC CIK 1507678 · EDGAR
BoughtSold
Most active insiders at RPRX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Coyne Terrance P. | EVP, CFO | — | $38.96M |
| 2 | Hite Christopher | EVP, Vice COB | — | $27.36M |
| 3 | Lloyd George W. | EVP, CLO, Investments | — | $13.81M |
| 4 | Urist Marshall | EVP, Research, Investments | — | $12.07M |
| 5 | Norden Gregory | Dir | — | $161.4K |
| 6 | Engelbert Catherine M. | Dir | — | — |
| 7 | Ho Carole | Dir | — | — |
| 8 | Coric Vlad | Dir | — | — |
| 9 | Bassler Bonnie L | Dir | — | — |
| 10 | Legorreta Pablo G. | CEO, COB, Dir | — | — |
Transactions 23
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-08-07 17:24 | 2026-08-05 | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, COB, Dir | A - Grant | $0.00 | +65.2K | 1.31M | +5% | $0 |
| 2026-05-08 17:17 | 2026-05-06 | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, COB, Dir | A - Grant | $0.00 | +143.8K | 1.24M | +13% | $0 | |
| 2026-02-13 | 2026-02-11 | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, COB, Dir | A - Grant | $0.00 | +157.8K | 1.10M | +17% | $0 | |
| 2025-11-07 | 2025-11-05 | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, COB, Dir | A - Grant | $0.00 | +36.6K | 941.0K | +4% | $0 | |
| D | 2025-08-08 | 2025-08-06 | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, COB, Dir | A - Grant | $0.00 | +21.9K | 904.4K | +2% | $0 |
| DI | 2025-06-05 | 2025-06-03 | PROK | PROKIDNEY CORP. | Legorreta Pablo G. | Dir, 10% | J - Other | $0.00 | -3.82M | 22.62M | -14% | $0 |
| DI | 2025-06-05 | 2025-06-03 | PROK | PROKIDNEY CORP. | Legorreta Pablo G. | Dir, 10% | C - Cnv Deriv | $0.00 | +3.82M | 26.44M | +17% | $0 |
| D | 2025-05-20 | 2025-05-16 | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, COB, Dir | J - Other | $0.00 | +530.3K | 882.5K | +151% | $0 |
| 2025-05-09 | 2025-05-08 | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, COB, Dir | A - Grant | $0.00 | +288.4K | 352.1K | +452% | $0 | |
| I | 2024-06-14 | 2024-06-13 | PROK | PROKIDNEY CORP. | Legorreta Pablo G. | Dir, 10% | P - Purchase | $2.42 | +22.62M | 22.62M | New | +$54.74M |
| DI | 2024-02-06 | 2024-02-05 | PROK | PROKIDNEY CORP. | Legorreta Pablo G. | Dir, 10% | J - Other | $0.00 | -749.0K | 0 | -100% | $0 |
| DI | 2024-02-06 | 2024-02-05 | PROK | PROKIDNEY CORP. | Legorreta Pablo G. | Dir, 10% | C - Cnv Deriv | $0.00 | +749.0K | 749.0K | New | $0 |
| I | 2023-11-16 | 2022-12-30 | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, COB, Dir, 10% | G - Gift | $0.00 | +292.2K | 292.2K | New | $0 |
| 2023-11-16 | 2023-11-16 | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, COB, Dir, 10% | J - Other | $0.00 | -383.0K | 63.8K | -86% | $0 | |
| DI | 2023-11-01 | 2023-10-30 | PROK | PROKIDNEY CORP. | Legorreta Pablo G. | Dir, 10% | C - Cnv Deriv | $0.00 | +5.29M | 5.29M | New | $0 |
| DI | 2023-11-01 | 2023-10-30 | PROK | PROKIDNEY CORP. | Legorreta Pablo G. | Dir, 10% | J - Other | $0.00 | -5.29M | 0 | -100% | $0 |
| I | 2023-06-28 | 2023-06-28 | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, COB, Dir, 10% | P - Purchase | $29.51 | +130.0K | 600.0K | +28% | +$3.84M |
| MI | 2023-06-13 | 2023-06-12+ | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, COB, Dir, 10% | P - Purchase | $32.89 | +90.0K | 425.0K | +27% | +$2.96M |
| I | 2023-05-24 | 2023-05-24 | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, COB, Dir, 10% | P - Purchase | $32.25 | +150.0K | 380.0K | +65% | +$4.84M |
| MI | 2023-05-17 | 2023-05-16+ | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, COB, Dir, 10% | P - Purchase | $33.38 | +230.0K | 230.0K | New | +$7.68M |
| D | 2022-04-15 | 2022-04-14 | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, COB, Dir, 10% | J - Other | $0.00 | -350.0K | 63.8K | -85% | $0 |
| DI | 2022-04-15 | 2022-04-14 | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, COB, Dir, 10% | J - Other | $0.00 | -462.0K | 0 | -100% | $0 |
| DMI | 2022-04-15 | 2020-06-16+ | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, COB, Dir, 10% | C - Cnv Deriv | $0.00 | +922.2K | 493.8K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations